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SObjective: Surgical resection has been the mainstay of curative treatment of early stage lung cancer in selected
patients. We evaluated survival and patterns of recurrence after surgical resection for early stage lung cancer
from the American College of Surgeons Oncology Group Z0030/Alliance trial.
Methods: One thousand eighteen patients enrolled in the Z0030 trial were analyzed according to clinical T stage.
Differences between groups were compared using the 2-sample rank test or c2 test. Log rank test and Cox propor-
tional hazards regressionwere used to compare survival and recurrence. To compare patients who underwent open
versus video-assisted thoracoscopic surgery (VATS) resections, propensity-score matched analysis was per-
formed. Seven hundred fifty-two patients (66 undergoingVATS and 686 undergoing open surgery) were classified
into 5 equal-sized propensity-score groups. Proportional hazards regression was used to compare these outcomes.
Results: There were 578 patients with cT1 tumors and 440 patients with cT2 tumors. Median follow-up was 6.7
years. Median overall survival was 9.1 years (stage T1) and 6.5 years (stage T2). Overall survival at 5 years was
72% (stage T1) and 55% (stage T2). Local recurrence-free survival at 5 years was 95% (stage T1) and 91%
(stage T2) (P ¼ .015). Among patients with stage T1 cancer, 4.2% (23 out of 542) had local recurrences,
whereas 7.3% (30 out of 409) of those with stage T2 tumors had local failure. There was no difference in the
development of new primary tumors between stage T1 and stage T2 groups. In the propensity-score matched
analysis of VATS versus open lobectomy patients, there was no difference in overall survival, disease-free sur-
vival, and freedom from development of a new primary tumor.
Conclusions: Results of patients with resected early stage non–small cell carcinoma from a large-scale, multi-
center trial serve as benchmarks against which to compare nonsurgical therapies for early stage lung cancer.
Propensity-score matched analysis shows no difference in survival between patients undergoing VATS and
open lobectomy. (J Thorac Cardiovasc Surg 2014;147:747-53)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and CaOutcomes of surgical treatment are needed to serve as refer-
ence points against which to compare the outcomes of these
nonsurgical therapies in early stage lung cancer.
We performed a secondary analysis of a large-scalemulti-
center, randomized trial to determine the long-term clinical
outcomes of patients undergoing surgical treatment for
early stage NSCLC. The American College of Surgeons
Oncology Group (ACOSOG) Z0030 (Alliance) trial was a
prospective, randomized, multi-institutional clinical trial
that was designed to determine the effect on survival of
lymph node sampling versus mediastinal lymph node
dissection in patients undergoing complete resection of early
stage NSCLC.1 Once the primary endpoints of the study
were reached, we secondarily analyzed the data to determine
overall survival and patterns of recurrence. The advantages
of this dataset include the rigor and uniformity with which
the trial was conducted regarding eligibility criteria, staging
procedures, data collection, and surgical techniques as well
as the fact that these datawere audited. The long-term results
derived from this study serve as benchmark data against
which to compare the results of more recent nonsurgical
therapies for the treatment of early stage lung cancer.rdiovascular Surgery c Volume 147, Number 2 747
TABLE 1. Characteristics of patients in the American College of
Surgeons Oncology Group Z0030/Alliance trial by clinical
classification (n ¼ 1023)
Clinical classification n %
T stage
cT1 578 57
cT2 440 43
Pathologic stage
IA 423 41
IB 418 41
IIA 37 4
IIB 97 9
IIIA 26 3
IIIB 19 2
Abbreviations and Acronyms
ACOSOG ¼ American College of Surgeons
Oncology Group
NSCLC ¼ non–small cell carcinoma
VATS ¼ video-assisted thoracoscopic surgery
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Details of the study design, eligibility requirements, and the morbidity
and mortality of patients enrolled in the ACOSOG Z0030 (Alliance) trial
have been previously reported.1,2 The protocol was approved by a central
institutional review board in addition to the institutional review board at
each participating institution. All patients provided written informed
consent before trial enrollment. In summary, eligible patients were
required to be older than age 18 years, to have an Eastern Cooperative
Oncology Group performance status lower than 3, and a tissue diagnosis
of NSCLC clinical stage T1 or T2, N0 or non-hilar N1, M0 before random-
ization. Eligible patients had to be candidates for resection by means of
pneumonectomy, lobectomy, bilobectomy, or segmentectomy. The type
of resection (video-assisted thoracoscopic surgery [VATS] vs open) was re-
corded in the dataset. Patients with N2 metastases were excluded from
randomization.
There were 1023 eligible patients who were evaluated for the following
long-term outcomes: local, locoregional, distant recurrence, disease-
specific, and overall survival (5 were excluded because clinical stage was
not reported in the database). Thus in this study we evaluated 1018 patients
by clinical T classification: 578 patients with T1 tumors and 440 patients
with T2 tumors. Based on the Z0030 dataset definitions, recurrence was
defined as local if it occurred in the adjacent lung parenchyma, bronchial
stump, or the hilum adjacent to the bronchial stump. It was defined as
regional if it occurred in the hilum (separate from bronchial stump), medi-
astinum, chest wall, or ipsilateral pleura. Recurrence was defined as distant
if it occurred in a separate lobe of ipsilateral lung, contralateral thorax,
supraclavicular lymph nodes, or distant organ.
Statistical Methods
Differences between groups with regard to clinical and tumor character-
istics were compared using the 2-sample rank test or c2 test as appropriate.
Cumulative survival probabilities were estimated using the Kaplan-Meier
method. The log rank test and Cox proportional hazards regression were
used to compare survival and recurrence across groups.
As an additional analysis, we evaluated the Z0030 dataset based on
propensity-score matching to compare patients who underwent open
versus VATS anatomic lung resections.3 Clinical and tumor characteris-
tics were used to build a propensity score for choice of treatments. These
variables included age, sex, histology, performance status, tumor location,
and clinical T classification (T1 vs T2). Propensity scores were developed
to estimate the adjusted risks of perioperative outcomes associated with
the approach of treatment (VATS vs open). Logistic regression was
used to estimate the probability of VATS versus open given the previously
listed risk factors. Patients were classified into 7 groups based on their
propensity scores. Two hundred eight thoracotomy patients had lower
scores than the lowest score of any VATS patient treated (group 0); 4
open lobectomy patients had higher scores than the highest VATS patient
treated (group 6). Patients from these 2 groups were omitted from further
analysis.3 The remaining 752 patients (66 in the VATS group and 686 in
the open lobectomy group) were classified into 5 equal-sized propensity
score groups (groups 1-5). Proportional hazards regression with 5 strata
(propensity score groups 1-5) was used to compare long-term outcomes
between patients undergoing VATS and those undergoing an open
procedure.748 The Journal of Thoracic and Cardiovascular SurgRESULTS
Overall Survival
There were 1018 patients who were evaluated by clinical
T classification: 578 patients with T1 tumors and 440 pa-
tients with T2 tumors. The stratification by clinical T clas-
sification is shown in Table 1. Median follow-up was 6.7
years in the entire cohort. The median overall survival for
patients with T1 tumors was 9.1 years, whereas that for
those with T2 tumors was 6.5 years. Overall survival and
disease-free survival for clinical T1 and T2 patients are
shown in Table 2.
The 5-year overall survival was 72% for T1 patients
and 55% for T2 patients (P< .001) (Figure 1). Disease-
free survival at 5 years was 77% for patients with T1 tu-
mors and 58% for those with T2 tumors (P < .001)
(Figure 2).
Local and Locoregional Recurrence
The 5-year local recurrence-free survival for the T1
cohort was 95% and for T2 group 5-year local
recurrence-free survival was 91% (P ¼ .015).
The 5-year locoregional recurrence-free survival was
88% for T1 patients, 84% for T2 patients (P ¼ .044).
The 5-year distant disease-free survival for the T1 patients
was 83% and for the T2 patients was 66% (P< .001)
(Table 2).
Of 542 patients with T1 tumors assessed for recurrence,
4.2% had local recurrences and 17.3% had distant metasta-
ses. Among patients with T1 tumors who were reported to
develop recurrent tumor (125 patients), 6% of total recur-
rences were local alone, whereas 75.2% of recurrences
were distant in nature (Table 3).
Of 409 patients with T2 tumors assessed for recurrence,
7.3% had local recurrences and 30.8% had distant metasta-
ses. Among patients with T2 tumors who developed recur-
rent tumor (156 patients), 8% of total recurrences were
purely local, whereas 80.8% of recurrences included distant
metastases (Table 3).ery c February 2014
TABLE 2. Long-term outcomes in patients with clinical stage T1 and T2 tumors
T1 (n ¼ 578) T2 (n ¼ 440)
HR 95% CI PMedian 5-year survival (95% CI) Median 5-year survival (95% CI)
Overall survival 9.1 72 (68-76) 6.5 55 (51-60) 1.64 1.36-1.99 <.001
Disease-free survival* NA 77 (73-81) NA 58 (53-64) 1.88 1.49-2.38 <.001
Local disease-free survivaly NA 95 (93-97) NA 91 (88-94) 1.96 1.14-3.37 .015
Local/regional disease-free
survivalz
NA 88 (85-91) NA 84 (80-88) 1.46 1.01-2.11 .044
Distant disease-free survivalx NA 83 (79-86) NA 66 (61-71) 1.99 1.53-2.61 <.001
New primaryjj 9 83 (79-86) NA 84 (80-87) 0.84 0.61-1.16 .29
HR, Hazard ratio; CI, confidence interval; NA, median survival not achieved. *Disease-free survival (n ¼ 542 (125 events) in the T1 group and n ¼ 409 (156 events) in the T2
group): deaths are censored. yLocal disease-free survival (n¼ 542 [23 events] in the T1 group and n¼ 409 [30 events] in the T2 group): deaths and regional/distant recurrence are
censored. zLocal/regional disease-free survival (n¼ 542 [57 events] in the T1 group and n¼ 409 [56 events] in the T2 group): deaths and distant recurrence are censored. xDistant
disease-free survival (n¼ 542 [94 events] in the T1 group and n ¼ 409 [126 events] in the T2 group): deaths and local/regional recurrence are censored. jjNew primary (n¼ 564
[101 events] in the T1 group and n ¼ 432 [57 events] in the T2 group): deaths are censored.
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There was no significant difference in the numbers of pa-
tients who developed new primary tumors in comparing the
T1 and T2 groups. At 5 years, 83% of patients with T1 tu-
mors and 84% of those with T2 tumors remained free of
new primary tumors (P ¼ .29) (Table 2).
Propensity-Score Matched Analysis of VATS Versus
Open Lobectomy Patients
An additional analysis was performed to evaluate VATS
versus open lobectomy patients based on propensity-score
matched groups of the Z0030 cohort. The patient demo-
graphics for this analysis are shown in Table 4. Median
follow-up was 7 years for the VATS patients (n ¼ 66)
and 6.7 years for the open lobectomy patients
(n ¼ 686). Overall survival between the VATS and open
lobectomy groups were similar. The median overall
survival for the VATS group was not achieved, and theFIGURE 1. Overall survival, by cancer stage (T1 vs T2).
The Journal of Thoracic and Ca5-year survival was 71.6% (95% confidence interval
[CI], 61.3%-83.6%). The median overall survival for the
open lobectomy group was 8.4 years, and the 5-year sur-
vival was 65.9% (95% CI, 62.3%-69.7%) (P ¼ .36)
(Figure 3).
There was no difference in disease-free survival between
the 2 groups (Figure 4). There were 13 (20%) patients in the
VATS group who had a recurrence and 193 (28%) patients
in the open lobectomy group. Median disease-free survival
was not achieved in either the VATS or open lobectomy
groups. There was no difference in 5-year disease-free sur-
vival: 75.2% in the VATS group, and 69.2% in the open lo-
bectomy group (P ¼ .55) (Table 5). Locoregional
recurrence-free survival was similar between the 2 groups.
The 5-year locoregional disease-free survival was similar,
82.0% in the VATS group and 86.1% in the open lobec-
tomy group (P ¼ .58). Distant recurrence-free survival
was also similar between the 2 groups. The 5-year distantFIGURE 2. Disease-free survival, by cancer stage (T1 vs T2).
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TABLE 3. Patterns of recurrences in the American College of
Surgeons Oncology Group Alliance trial Z0030 data set, by clinical
stage
T1 (n ¼ 542) T2 (n ¼ 409)
Local 7 (1) 13 (3)
Regional 22 (4) 13 (3)
Distant 68 (13) 99 (24)
Local/regional 2 (0.4) 3 (0.7)
Local/distant 10 (2) 9 (2)
Regional/distant 12 (2) 13 (3)
Local/regional/distant 4 (0.7) 5 (1)
Total No. of patients with
recurrences
125 156*
Data are presented as n (%), unless otherwise indicated. *Location of recurrence was
not indicated for 1 subject.
TABLE 4. Patient demographics for patients included in the
propensity-based analysis
VATS
(n ¼ 66)
Open lobectomy
(n ¼ 686) P*
Age, y 72.9 (70.9  9.7) 68.6 (68.1  8.8) .011 (.38)
Sex .15
Women 38 (57.6) 331 (48.3) (.99)
Men 28 (42.4) 355 (51.8)
Histology .029
Squamous cell 10 (15.2) 206 (30.0) (.99)
Adenocarcinoma 45 (68.2) 354 (51.6)
Large cell 2 (3.0) 36 (5.3)
Bronchoalveolar 8 (12.1) 57 (8.3)
Other non–small cell
carcinoma
1 (1.5) 33 (4.8)
Performance status .002
0 60 (90.9) 488 (71.1) (.18)
1 5 (7.6) 192 (28.0)
2 1 (1.5) 6 (0.9)
Tumor location .69
RUL 32 (48.5) 284 (41.4) (.99)
RML 2 (3.0) 44 (6.4)
RLL 8 (12.1) 112 (16.3)
LUL 18 (27.3) 173 (25.2)
LLL 7 (10.6) 85 (12.4)
Clinical stage .26
T1 44 (66.7) 408 (59.5) (.89)
T2 22 (33.3) 278 (40.5)
Pathologic T-stage .78
T1 37 (56.1) 328 (48.0) (.98)
T2 27 (40.9) 329 (48.2)
T3 1 (1.5) 16 (2.3)
T4 1 (1.5) 10 (1.5)
Pathologic N-stage .5
N0 61 (92.4) 592 (86.5) (.65)
N1 5 (7.6) 81 (11.8)
N2 0 (0) 11 (1.6)
Pathologic stage .54
IA 35 (53.0) 297 (43.5) (.80)
IB 25 (37.9) 275 (40.3)
IIA 2 (3.0) 28 (4.1)
IIB 3 (4.6) 58 (8.5)
IIIA 0 (0) 15 (2.2)
IIIB 1 (1.5) 10 (1.5)
Values are presented as n (%) or median (mean  standard deviation). VATS, Video-
assisted thoracic surgery; RUL, right upper lobe; RML, right middle lobe; RLL, right
lower lobe; LUL, left upper lobe; LLL, left lower lobe. *c2 test for categorical
variables and 2-sample t test (rank sum test) for continuous variables. P values in pa-
rentheses are Cochran-Mantel-Haenszel tests for categorical variables or linear
models for continuous variables demonstrating that patient characteristics were
similar across treatment groups after adjusting for propensity score groups.
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75.3% in the open lobectomy group (P ¼ .20).
There was no statistical difference between the 2 groups
in the time to development of a new primary tumor. The
new primary tumor-free survival at 5 years was 87.8% in
the VATS group and 81.7% in the open lobectomy group.
There were 7 patients (11%) in the VATS group who had
a new primary tumor, of which 4 were of lung origin. There
were 118 patients (17%) in the open lobectomy group who
had a new primary tumor, of which 34 were of lung origin.
DISCUSSION
To date the ACOSOG Z0030 (Alliance) trial is the largest
prospective randomized trial of patients with early stage
NSCLC undergoing surgical resection in the United States.
Thus the outcomes of resected clinical T1 and T2 NSCLC
reported in this study provide important points of reference
with which to compare results of nonsurgical treatments,
which are being more often considered as alternatives to
surgery in both inoperable and operable patients. These
therapies are difficult to compare due to lack of uniformity
in staging, pathologic confirmation, patient selection, inter-
pretations of post-treatment response, and nonstandard
treatment protocols (eg, fractionation and dose prescription
regarding stereotactic body radiation therapy). Addition-
ally, the radiographic definition of successful local control
in patients treated with nonsurgical ablation is broad,
including partial response, stable disease, as well as com-
plete response by either computed tomography or positron
emission tomography/computed-tomography scan. For
example, an important consideration in evaluation of stereo-
tactic body radiation therapy outcomes is that local control
often refers to the radiographic response in the tumor bed
alone, whereas local control in the surgical literature in-
cludes failure in the ipsilateral lobe, hilum, and ipsilat-
eral/contralateral mediastinum.
The Z0030 cohort included patients who were clinically
staged as having stage I NSCLC, although ultimately it rep-
resented those who were N2 and hilar N1 node-negative on750 The Journal of Thoracic and Cardiovascular Surginitial nodal sampling before being randomized into the trial.
In spite of this, 18% were found to have a pathologic stage
more advanced than stage I, with 13% harboring occult N1
disease and 2% with occult N2 disease. Recent studies eval-
uating patients with clinical stage I NSCLC who underwent
surgical resection report 29% to 35% pathologic upstaging
at surgery.4,5 In the absence of pathologic staging, patientsery c February 2014
TABLE 5. Long-term outcomes in propensitymatched groups of patients undergoing video-assisted thoracic surgery (VATS) and open lobectomies
VATS (n ¼ 66) Lobectomy (n ¼ 686)
HR 95% CI PMedian 5-year survival,% (95%CI) Median 5-year survival,% (95%CI)
Overall survival NA 71.6 (61.3-83.6) 8.4 y 65.9 (62.3-69.7) 1.22 0.8-1.87 .36
Disease-free survival* NA 75.2 (63.5-89.1) NA 69.2 (65.4-73.3) 1.19 0.67-2.10 .55
Local disease-free survivaly NA 88.0 (78.6-98.5) NA 92.6 (90.2-95.0) 0.58 0.23-1.50 .26
Local/regional disease-free
survivalz
NA 82.0 (71.5-94.1) NA 86.1 (83.1-89.2) 0.81 0.39-1.70 .58
Distant disease-free survivalx NA 87.4 (77.6-98.4) NA 75.3 (71.7-79.1) 1.65 0.77-3.55 .20
New primaryjj NA 87.8 (79.6-96.8) 9.0 81.7 (78.3-85.3) 1.71 0.79-3.72 .17
HR, Hazard ratio; CI, confidence interval; NA, median survival not achieved. *Disease-free survival (n¼ 47 in the VATS group and n¼ 652 in the lobectomy group). Deaths are
censored. yLocal disease-free survival (n ¼ 47 in the VATS group and n ¼ 652 in the lobectomy group). Deaths and regional/distant recurrence are censored. zLocal/regional
disease-free survival (n ¼ 47 in the VATS group and n ¼ 652 in the lobectomy group). Deaths and distant recurrence are censored. xDistant disease-free survival (n ¼ 47 in the
VATS group and n ¼ 652 in the lobectomy group). Deaths and local/regional recurrence are censored. jjNew primary (n ¼ 64 in the VATS group and n ¼ 673 in the lobectomy
group). Deaths are censored.
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understaging. Yet studies of these latter treatments report
low rates of local failure; for example, the Radiation
Therapy Oncology Group 0236 trial (which enrolled
patients with cT1-2N0 NSCLC for treatment by stereotactic
body radiation therapy) reported a 3-year primary tumor con-
trol of 97.6% and local control of 90.6%.6 One rationale
behind such low rates of local failure may be that studies per-
formed in patients deemedmedically inoperable due to other
comorbidities underrepresent actual rates of failure on ac-
count of censoring patients who die as a result of noncancer
causes without documentation of recurrence.
Thus far, absence of long-term follow-up in studies
involving nonsurgical treatments so far precludes forma-
tion of any guidelines for potentially operable candidates
with early stage NSCLC. Long-term follow-up is required
because local recurrence has been shown to occur at theFIGURE 3. Overall survival, video-assisted thoracic surgery (VATS)
versus open lobectomy.
The Journal of Thoracic and Casite of primary tumor after an extended period following
treatment (10 years).7,8 Recent data from the completed
Radiation Therapy Oncology Group 0618 trial, which
evaluated operable patients undergoing stereotactic body
radiation therapy for early stage NSCLC report local
failure (primary tumor plus involved lobe failure) rates
of 19.2% at 2 years.9 In contrast, within the Z0030
cohort the local failure rate was 4% in the T1 patients
and 7% in the T2 patients at a median follow-up of 6.7
years. Because the outcomes in our study evaluated the
Z0030 cohort by clinical T1 and T2 classification
(without regard to eventual pathologic stage), they repre-
sent important points of reference for comparison with
outcomes of nonsurgical treatment in patients of similar
early stage.
Our analysis of the Z0030 data shows that the long-term
outcomes between patients who underwent VATSFIGURE 4. Disease-free survival, video-assisted thoracic surgery (VATS)
versus open lobectomy.
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cer are similar. There was no difference in overall survival,
disease-free survival, or survival based on pattern of recur-
rence. There was no difference in time to locoregional
recurrence between the VATS and open lobectomy groups.
Based on the given data, the conclusion that VATS provides
local control at least equivalent to that provided by thoracot-
omy is validated. Concern has been raised that VATS lobec-
tomy for clinical T1-2 N0 NSCLC may lead to less
complete N1 lymph node evaluation and lower rates of
N1 upstaging compared with open lobectomy. Such detec-
tion of nodal involvement may extend the potential benefits
of adjuvant chemotherapy to patients who otherwise would
be offered none. The results of this study are unable to
address this concern because the rate of pN1 involvement
was low in both VATS and open lobectomy groups (8%
and 12%, respectively; P ¼ .49).
In the past, those who doubted the validity of the VATS
lobectomy approach raised concerns that small lung lesions
representative of synchronous primary tumors or metastatic
disease may miss the opportunity for detection by bimanual
palpation at the time of initial operation. This study shows
that the numbers of patients who develop second primary
tumors are not different between the VATS and open lobec-
tomy approach. This finding is in agreement with the con-
clusions of a recent single-institution study that showed
similar incidence of second primary tumors following
lobectomy by VATS versus open technique.10
The limitations of this study include the fact that positron
emission tomography/computed tomography was not
required for entry into the trial; thus clinical staging by
this means was not uniformly used. Data collected in
follow-up was limited by return of data forms by the partici-
pating institutions. VATS sample size for the propensity-
matched analysis was limited. At the time that the trial
was conducted, adjuvant chemotherapy was not the stan-
dard of care for node-positive disease or tumors of size 4
cm or larger.11 These nonetheless do not undermine the
relevance of the reported outcomes in patients undergoing
surgical resection with early stage NSCLC.CONCLUSIONS
As nonsurgical treatments are more commonly used in
treatment of early stage NSCLC, a critical evaluation of
outcomes should be performed. The survival data and recur-
rence patterns following surgical treatment of clinical T1 and
T2 lung cancers in the Z0030 cohort serve as benchmarks
against which the outcomes of ablative techniques such as
stereotactic body radiation therapy must be compared.References
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Dr Scott J. Swanson (Boston, Mass). Dr Su, that was an excel-
lent presentation, and you showed extreme poise while you were
waiting for your slides.
What is your message? Is it that we should pursue more mini-
mally invasive strategies or their equivalent? I think I understand
what you were getting at, but do you have a conclusion from
what you presented here?
Dr Su. Thank you for your question and kind comments,
Dr Swanson. There are several messages one can take from these
data. Themain one is that these data are issued from the largest ran-
domized trial in the U.S. of surgical treatment for early-stage lung
cancer. In terms of recurrence rates and survival, they represent a
benchmark against which nonsurgical therapies (such as stereotac-
tic body radiation therapy [SBRT] or radio-frequency ablation)
must be compared. Additionally, these data provide continued sup-
port for the use of minimally invasive surgery as compared with
open surgery in that recurrence rates, freedom from second pri-
maries, and long-term survival of matched, early-stage lung cancer
patients were similar regardless of surgical approach.
Dr Swanson. I have 1 further question. What do you make out
of articles we have heard about recently about lymph node dissec-
tion or sampling or removal with video-assisted thoracoscopic sur-
gery (VATS) versus open? It seems like your data show anery c February 2014
Su et al General Thoracic Surgeryequivalent ability to get local and locoregional control. Is the cor-
rect conclusion that a VATS approach is equally good to getting
local and regional control—meaning getting out lymph nodes—
for early stage lung cancer? Am I understanding that correctly?
Dr Su. The VATS versus open lobectomy question is relevant
because VATS has been suggested to have a lower risk profile,
and the benefits of SBRT lie in its noninvasiveness and minimal
risks. With regard to the lymph node dissection, only 7% of Z30
trial patients underwent VATS lobectomy. So these data are as
good as it gets in terms of offering best outcomes, because most
of the patients underwent open lobectomy.
DrM.BlairMarshall (Washington,DC). I just have a comment.
I would like to commend Stacey for taking this on. The stereotactic
body radiation literature often compares resultswith old surgical re-
sults, not current data. It is important to continually update our re-
sults. There is too much variability in the literature and the
definition of a local recurrence is variable in much of the stereotac-
tic radiation literature. Those patientswho aremedically inoperable
may never be sent for a biopsy of their recurrence. We have had no
rigorous analysis of the data or outcomes in these studies. It is
important to participate in these trials and have adequate follow-
up of our patients. With the reports currently in the literature, and
the very short-term outcomes being reported, radiation may seem
like an equivalent alternative to surgery. However I am fairly certain
that longer-term data will show that not to be the case.
Dr Raphael Bueno (Boston, Mass). Stacey, that was a great
presentation.
Because you had a large number of patients and they are very
much annotated, is it possible for you to look at those who areThe Journal of Thoracic and Caolder, are the most frail, with the worst pulmonary function and
additional comorbidities? Looking at the data for T1 is not going
to make 90% much worse, but it will be potentially more compa-
rable, and we can show that even in that population we do better. Is
that something you can do?
Dr Su. Sure, that can be looked at. The Z30 trial was essentially
looking at mediastinal nodal sampling versus dissection and the
groups were randomized according to those criteria, but certainly
that is something that can be looked into.
Dr David J. Sugarbaker (Boston, Mass). Very nice presenta-
tion, Dr Su. I have just a question about preoperative staging,
particularly in the T2 lesions. Was there any systematic review
as to which patients would have preoperative endobronchial ultra-
sound or mediastinoscopy?
Dr Su. The Z30 trial required patients to be nodenegative from
the standpoint of N2 nodes and hilar N1 nodes. These patients were
staged according to mediastinoscopy in addition to VATS and tho-
racotomy. Endobronchial ultrasound was not utilized during the
time period of the study.
Dr Sugarbaker. How about positron emission tomography
scans?
Dr Su. Positron emission tomography scans were not consis-
tently used. The study was conducted before those scans were
widely available.
Dr Bueno. But you looked at all T1s regardless of what the
N status was to mimic what the SBRT people might be doing?
Dr Su. SBRT data is often quoted in terms of T1 and T2.
Dr Bueno. So some of your T1s were stage II, potentially?
Dr Su. These were pathologic T1 and pathologic T2 data.rdiovascular Surgery c Volume 147, Number 2 753
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